超声引导下射频消融联合经肝动脉化疗栓塞治疗肝细胞癌的疗效和安全性：一项荟萃分析。

OBJECTIVE

Meta-analysis was used to assess the efficacy and safety of ultrasound-guided radiofrequency ablation combined with transhepatic artery embolization chemotherapy for hepatocellular carcinoma.

METHODS

Randomized controlled studies on ultrasound-guided radiofrequency ablation combined with transhepatic artery embolization chemotherapy for hepatocellular carcinoma were searched in the databases of PubMed, Embase, Cochrane library, web of science with a search deadline of March 14, 2024. Data were analyzed using Stata 15.0.

RESULT

Six randomized controlled studies involving 520 individuals were finally included, the results of meta-analysis showed that ultrasound-guided radiofrequency ablation combined with TACE can improve objective response rate [RR = 1.52, 95%CI (1.28, 1.81)], improve disease control rate [RR = 1.15, 95%CI (1.06, 1.24)], The survival rate [RR = 1.34, 95%CI (1.19,1.51)] did not increase adverse reactions [RR = 1.34, 95%CI (1.00,1.79)].

CONCLUSION

Based on the findings of the current study, ultrasound-guided radiofrequency ablation combined with TACE was found to improve the objective remission rate, disease control rate, and did not increase adverse events in patients with hepatocellular carcinoma.

目的

采用荟萃分析评估超声引导下射频消融联合经肝动脉化疗栓塞治疗肝细胞癌的疗效和安全性。

方法

检索 2024 年 3 月 14 日前在 PubMed、Embase、Cochrane 图书馆、Web of Science 数据库中发表的关于超声引导下射频消融联合经肝动脉化疗栓塞治疗肝细胞癌的随机对照研究。采用 Stata 15.0 进行数据分析。

结果

最终纳入 6 项随机对照研究，共 520 例患者，荟萃分析结果显示，超声引导下射频消融联合 TACE 可提高客观缓解率[RR=1.52，95%CI（1.28，1.81）]，提高疾病控制率[RR=1.15，95%CI（1.06，1.24）]，生存率[RR=1.34，95%CI（1.19，1.51）]并未增加不良反应[RR=1.34，95%CI（1.00，1.79）]。